GT Biopharma Inc
GTBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.11M
Close$
$1.24
301.2% upside
Current Fair Value
301.2% upsideUndervalued by 301.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.11 Million |
|---|---|
| Enterprise Value | $4.15 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.25 |
| Beta | 0.9 |
| Outstanding Shares | 34,575,429 |
Return
| Return on Equity | -953.54% |
|---|---|
| Return on Assets | -587.98% |
| Return on Invested Capital | -1106.00% |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | -0.03 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.01%▲ 1.68% |
|---|---|
| Total Invested | $1.03M▲ 57.48% |
| Investors Holding | 58▲ 19.00% |
ESG Score
No data
About GT Biopharma Inc
2,018 employees
CEO: Anthony Cataldo GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is desig...